Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968562 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2458 (Electronic) Linking ISSN: 14712458 NLM ISO Abbreviation: BMC Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
    • Abstract:
      Background: There is evidence indicating that both lipoprotein(a) [Lp(a)] and fibrinogen (FIB) are associated with mortality, However, the impact of their combination on mortality has not been determined. Thus, the aim of this study was to examine the association between the combination of Lp(a) and FIB with all-cause and cause-specific mortality.
      Methods: This prospective cohort study enrolled 4,730 participants from the third National Health and Nutrition Examination Survey. The exposure variables included Lp(a), FIB and their combination, while the outcome variables consisted of all-cause, cardiovascular disease (CVD) and cancer-related mortality. Multivariate COX regression, subgroup analysis, sensitivity analysis and restricted cubic spline (RCS) were used to investigate the association between Lp(a), FIB and their combination with all-cause, CVD and cancer-related mortality.
      Results: Over a median follow-up period of 235 months, 2,668 individuals died, including 1,051 deaths attributed to CVD and 549 deaths due to cancer. Multivariate Cox regression analyses revealed independent associations between both Lp(a) and FIB with all-cause, CVD, and cancer-related mortality. Compared to participants in the 1st to 50th percentiles of both Lp(a) and FIB, those in the 90th to 100th percentiles exhibited multivariable adjusted HRs of 1.813 (95% CI: 1.419-2.317, P < 0.001), 2.147 (95% CI: 1.483-3.109, P < 0.001) and 2.355 (95% CI: 1.396, 3.973, P = 0.001) for all-cause, CVD and cancer-related mortality, respectively. Subgroup and sensitivity analyses did not substantially attenuate the association between the combination of high Lp(a) and high FIB with the risk of all-cause and CVD-related mortality. Additionally, the RCS analysis showed that the relationship between Lp(a) and the risk of all-cause and cancer-related mortality, as well as the relationship between FIB and the risk of cancer-related mortality, were linear (P for nonlinearity > 0.05). Conversely, the relationship between Lp(a) and the risk of CVD-related mortality, as well as the relationship between FIB and the risk of all-cause and CVD-related mortality, were nonlinear (P for nonlinearity < 0.05).
      Conclusions: High levels of Lp(a) and FIB together conferred a greater risk of mortality from all-cause, CVD and cancer.
      (© 2024. The Author(s).)
    • References:
      Clin Cardiol. 2004 May;27(5):258-64. (PMID: 15188938)
      J Transl Med. 2020 Oct 1;18(1):373. (PMID: 33004038)
      Vital Health Stat 1. 2013 Aug;(56):1-37. (PMID: 25078429)
      Thromb Haemost. 2018 Apr;118(4):778-790. (PMID: 29458232)
      Front Nutr. 2023 Jan 19;10:937771. (PMID: 36742423)
      Haematologica. 2006 Dec;91(12):1613-20. (PMID: 17145597)
      JAMA. 2009 Jul 22;302(4):412-23. (PMID: 19622820)
      Atherosclerosis. 2020 Nov;312:54-59. (PMID: 32977121)
      Thromb Res. 2021 Feb;198:182-189. (PMID: 33360152)
      Thromb Haemost. 2014 Oct;112(4):649-58. (PMID: 25182841)
      Lancet Diabetes Endocrinol. 2017 Jul;5(7):524-533. (PMID: 28408323)
      Clin Appl Thromb Hemost. 2007 Jan;13(1):35-42. (PMID: 17164494)
      Med J Aust. 2017 Feb 20;206(3):141. (PMID: 28208049)
      Eur Heart J. 2019 Sep 1;40(33):2760-2770. (PMID: 30608559)
      J Am Heart Assoc. 2017 Nov 18;6(11):. (PMID: 29151032)
      Circulation. 2016 Aug 23;134(8):611-24. (PMID: 27496857)
      Lancet. 2018 Nov 10;392(10159):1736-1788. (PMID: 30496103)
      Ann Epidemiol. 2009 Aug;19(8):592-6. (PMID: 19406663)
      Vital Health Stat 2. 1992 Sep;(113):1-35. (PMID: 1413563)
      Eur J Intern Med. 2017 Jan;37:49-55. (PMID: 27553697)
      Nat Genet. 2009 Mar;41(3):283-5. (PMID: 19198611)
      J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. (PMID: 28183512)
      J Am Coll Cardiol. 2022 Feb 15;79(6):545-558. (PMID: 35144746)
      Ann Intern Med. 1993 Jun 15;118(12):956-63. (PMID: 8489110)
      J Lipid Res. 2008 Oct;49(10):2230-9. (PMID: 18594118)
      Clin Chem. 2021 Jan 8;67(1):154-166. (PMID: 33236085)
      Prev Med. 2020 Oct;139:106044. (PMID: 32097752)
      J Lipid Res. 2016 Aug;57(8):1339-59. (PMID: 27074913)
      Lipids Health Dis. 2019 Jul 8;18(1):150. (PMID: 31286992)
      JAMA. 2005 Oct 12;294(14):1799-809. (PMID: 16219884)
      Clin Biochem. 2004 May;37(5):333-43. (PMID: 15087247)
      Thromb Res. 2014 May;133 Suppl 1:S38-40. (PMID: 24759140)
      Semin Thromb Hemost. 2017 Sep;43(6):614-620. (PMID: 28346964)
      Thromb Res. 2014 May;133(5):863-7. (PMID: 24502962)
      Proc Natl Acad Sci U S A. 1989 May;86(10):3847-51. (PMID: 2524834)
      J Nutr. 1990 Nov;120 Suppl 11:1451-4. (PMID: 2243286)
      Acta Pathol Microbiol Scand. 1963;59:369-82. (PMID: 14064818)
      Eur J Intern Med. 2021 Sep;91:33-39. (PMID: 33972150)
      JAMA. 2009 Jun 10;301(22):2331-9. (PMID: 19509380)
      Public Health Nutr. 2019 Jul;22(10):1777-1785. (PMID: 30789115)
      QJM. 2014 Sep;107(9):701-13. (PMID: 24633257)
      Eur Heart J. 1995 Mar;16 Suppl A:60-3. (PMID: 7796834)
      J Clin Lipidol. 2020 Sep - Oct;14(5):695-706.e4. (PMID: 32739333)
      Vital Health Stat 1. 1994 Jul;(32):1-407. (PMID: 7975354)
      Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28. (PMID: 30559228)
      J Am Coll Cardiol. 2019 May 7;73(17):2163-2165. (PMID: 31047004)
      Thromb Res. 2019 May;177:130-135. (PMID: 30897531)
      Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. (PMID: 34647487)
      Curr Atheroscler Rep. 2021 Jun 19;23(8):41. (PMID: 34146181)
    • Grant Information:
      81900453, 82222007, 82170281, and U2004203 National Natural Science Foundation of China; 81900453, 82222007, 82170281, and U2004203 National Natural Science Foundation of China; 81900453, 82222007, 82170281, and U2004203 National Natural Science Foundation of China; Hohhot Healthcare Medical-2023030 Hohhot Healthcare Science and Technology Programme; ZYQR201912131 Henan Thousand Talents Program; 202300410362 Excellent Youth Science Foundation of Henan Province; 2021-CCA-ACCESS-125 Central Plains Youth Top Talent, Advanced funds; SBGJ202101012 Henan Province Medical Science and Technology Key Joint Project; 222102230025 Key Scientific and Technological Research Projects in Henan Province
    • Contributed Indexing:
      Keywords: Cancer mortality; Cardiovascular mortality; Fibrinogen; Lipoprotein(a); Mortality
    • Accession Number:
      0 (Lipoprotein(a))
      9001-32-5 (Fibrinogen)
    • Publication Date:
      Date Created: 20240718 Date Completed: 20240719 Latest Revision: 20240808
    • Publication Date:
      20240808
    • Accession Number:
      PMC11256372
    • Accession Number:
      10.1186/s12889-024-19443-4
    • Accession Number:
      39026192